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Abstract
OBJECTIVE: To elucidate the interaction between
hydrophilic lithospermic acid B and lipophilic tan-
shinoneⅡA in rats.
METHODS: A reliable high-performance liquid
chromatography method was adopted for simulta-
neous determination of lithospermic acid B and
tanshinone ⅡA in rat plasma, through which the
pharmacokinetic interaction between lithospermic
acid B and tanshinoneⅡA by intravenous injection
was investigated.
RESULTS: The simultaneous intravenous injection
of tanshinone ⅡA and lithospermic acid B signifi-
cantly altered the pharmacokinetic parameters of
both compounds when compared with the individ-
ual intravenous administration of each compound.
The area under the concentration-time curve of
tanshinone ⅡA and lithospermic acid B increased
by 18.35 and 59.31%, respectively. The mean reten-
tion time of tanshinone ⅡA and lithospermic acid
B increased, respectively, from 9.3 to 32.8 h and
20.2 to 49.1 h. The concomitant use of tanshinoneⅡA magnified the volume of distribution at steady
state (Vss) and time for the drug in the plasma to re-
duce the highest concentration by half (t1/2) of litho-
spermic acid B, while at the same time the Vss and t1/2
of tanshinone Ⅱ A changed significantly in the
presence of lithospermic acid B.
CONCLUSION: Lithospermic acid B and tanshinoneⅡA interact with each other following simultane-
ous intravenous injection in rats and this observa-
tion may expand the clinical use of Danshen (Radix
SalviaeMiltiorrhizae).
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Danshen (Radix Salviae Miltiorrhizae) was first men-
tioned in Shen Nong Ben Cao Jing.1 With the develop-
ment of traditional medical theory and clinical prac-
tice, the accumulation of empirical knowledge in the
use of the medicinal plants for the treatment of various
cardiovascular diseases, such as coronary artery disease
and angina pectoris, has grown.2-5
Danshen (Radix Salviae Miltiorrhizae) contains several
pharmacologically active compounds, especially tanshi-
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none ⅡA (lipid-soluble compound) and lithospermic
acid B (water-soluble compound). In Chinese Pharma-
copoiea,6 tanshinone ⅡA and lithospermic acid B are
selected as the marker components for the quality con-
trol of Danshen (Radix Salviae Miltiorrhizae). The
combined use of lithospermic acid B and tanshinoneⅡ
A has been shown to provide higher therapeutic effica-
cy for the treatment of angiocardiopathy.7 This may be
because of the simultaneous action of multiple mecha-
nisms that ameliorate the symptoms of angiocardiopa-
thy. Tanshinone Ⅱ A may protect the myocardium
against hypertrophy induced by angiotensinⅡ8 and in-
hibit oxidized low-density lipoprotein (oxLDL) prod-
ucts.9 Lithospermic acid B may increase cerebral blood
flow after ischemia,10 increase NO production by endo-
thelial cells11 and inhibit the angiotensin-converting en-
zyme (ACE).12
The current Danshen (Radix Salviae Miltiorrhizae)
preparations, including tanshinone ⅡA and lithosper-
mic acid B, are mainly for oral administration, but
both tanshinone ⅡA and lithospermic acid B are of
low systemic bioavailability via oral administration.13,14
The clinically used intravenous injections of Danshen
(Radix Salviae Miltiorrhizae) can be water-soluble or
lipid-soluble compounds, including both tanshinoneⅡ A and lithospermic acid B, which may produce a
markedly synergistic effect.
The present pharmacokinetic study is designed to eluci-
date the interaction between tanshinoneⅡA and litho-
spermic acid B in rats. The results showed that an inter-
action between tanshinone ⅡA and lithospermic acid
B exists.
MATERIALS ANDMETHODS
Chemicals
Reference substances of tanshinone ⅡA and lithosper-
mic acid B, protocatechuic aldehyde and diazepam ([in-
ternal standards of high-performance liquid chromatog-
raphy (HPLC) analysis of paclitaxel] were purchased
from the National Institute for the Control of Pharma-
ceutical and Biological Products (Beijing, China). Tan-
shinone ⅡA (with a purity of 53.5%) and lithosper-
mic acid B (with a purity of 95.5%) for the rat pharma-
cokinetic study were extracted in-house from Danshen
(Radix Salviae Miltiorrhizae) obtained from Zhongji-
ang Bio-technology Co., Ltd., (Sichuan, China). All
the other chemicals were reagent grade and all the sol-
vents were HPLC grade.
A submicron emulsion of Danshen (Radix Salviae Milt-
iorrhizae) (EMU-AB), containing both tanshinone Ⅱ
A and lithospermic acid B was prepared. A submicron
emulsion of tanshinoneⅡA (EMU-A), containing tan-
shinone ⅡA was prepared, and a submicron emulsion
of lithospermic acid B (EMU-B), containing lithosper-
mic acid B was prepared. These three submicron emul-
sions were prepared in the same way while they con-
tain different components of Danshen (Radix Salviae
Miltiorrhizae). Tanshinone ⅡA was the same concen-
tration in EMU-AB and EMU-A. EMU-AB and
EMU-B contained equivalent lithospermic acid B. All
three emulsions were prepared by High Pressure Ho-
mogenization (EmulsiFlex-C5, AVESTIN, Canada) at
200 kg ∙ cm ﹣ 2 and run through the apparatus seven
times. The mean particle diameter was 140-180 nm
and therewas an averageZeta potential of (﹣50±2)mV.
Animals
The adult, male Wistar rats (10 weeks old, 200-220 g;
license No. SCXK BJ 2011-0004, Beijing Specific
Pathogen Free Experimental Animal Technology Com-
pany Ltd.) were bred in the experimental animal cen-
ter, Bejing University of Chinese Medicine (standard
barrier system, license No. SYXK BJ 2011-0024). The
rats were acclimatized for at least 1 week in a 12-h
light/dark cycle with free access to standard feed and
water at an ambient temperature of 22-24 ℃ and 60%
relative humidity. The rats fasted for 12 h before the
pharmacokinetic study. Fifteen rats were enrolled in
the study. They were randomly divided into 3 groups
by a random number table method: EMU-AB group
(n = 5), EMU-A group (n = 5) and EMU-B group
(n = 5). The procedures of this study strictly complied
with the generally accepted international rules and reg-
ulations, releasing the animals' pain by ether inhalation
anesthesia.
Intravenous injection of EMU-AB, EMU-A and
EMU-B
The three groups of rats were given a single dose
(4 mL/kg) of EMU-AB, EMU-A and EMU-B by re-
spectively tail intravenous injection. The animals
were fasted throughout the experimentation period.
They were fixed by shelves and blood samples were
collected into heparinized tubes. The samples were
then immediately centrifuged at 26.8 g-force for 3 min
at 4 ℃ and the plasma was separated. A 20 μL ali-
quot of protocatechuic aldehyde (19.18 μg/mL) and
a 10 μL aliquot diazepam (92.00 μg/mL) were added
into a tube containing calibration standards and 100
μL of plasma samples. The mixture was extracted
with 1 mL of ethyl acetate after rigorous mixing for
60 s and centrifuged at 236.3 g-force for 15 min
at 4 ℃ , and this extraction procedure was repeated
twice. After collecting the organic phase, 15 μL 10%
HCl (v/v) was added to acidify the sample, then the
acidified sample was extracted with 1 mL ethyl ace-
tate by rigorous mixing for 1 min and centrifuged at
15 000 rpm for 15 min at 4 ℃ . The organic layers
were combined and transferred into a clean tube and
evaporated under a nitrogen stream at 20 ℃. The res-
idue was reconstituted in 100 μL acetonitrile 0.025%
(v/v) phosphoric acid (50∶50, v/v) solution. After
centrifuging at 236.3 g-force for 25 min at 4 ℃, 10 μL
of the supernatant was used for HPLC analysis.
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HPLC assay
The plasma concentrations of tanshinone Ⅱ A and
lithospermic acid B were determined using the validat-
ed reversed-phase HPLC approach with an ultraviolet
ray detection method. Briefly, a volume of 10 μL super-
natant was injected into the HPLC system for the anal-
ysis of tanshinone Ⅱ A and/or lithospermic acid B.
Analyses were carried out using a Varian series ProStar
HPLC system equipped with a ProStar 210 solvent de-
livery module and a ProStar 325 UV-vis detector. The
system control and data analysis were made using ProS-
tar® software (Varian Technologies Co., Ltd., Revision
6.3, Varian). The chromatographic separation of the
two components and internal standards was achieved
by using a reversed-phase HPLC column (SHIM-
PACK VP-ODS chromatographic column, 150 mm ×
4.6 mm I.D., 5 μm) protected by a guard column
(Chrom Guard HPLC C18 Column, 10 mm × 3 mm,
Varian). The mobile phase for gradient elution consist-
ed of two solvent systems: solvent A (0.025% , v/v,
phosphoric acid solution) and solvent B (acetonitrile).
Gradient elution was carried out as follows: 100% (v/
v) solvent A was used in the first minute, then the per-
centage of solvent B was linearly increased to 20% over
5 min, and then solvent B was increased to 50% at
5-25 min, to 95% at 25-37 min, and finally decreased
to 0% at 40 min. The flow rate was 1 mL/min. The de-
tection wavelength was set at 281 nm for lithospermic
acid B, internal standard protocatechuic aldehyde and
diazepam, and at 272 nm for tanshinoneⅡA. The col-
umn temperature was 30℃.
Pharmacokinetic analysis
Non-compartmental analysis of the data was per-
formed using statistical moment theory. In the area un-
der the plasma concentration versus time curve up to
the last quantifiable time point, AUC0-t was obtained
by linear trapezoidal summation. The AUC0-t was ex-
trapolated to infinity (AUC0-∞) by the equation AUC0-t
+ C/ke, where C represents the last measurable time
concentration and ke represents the terminal elimina-
tion rate constant. ke was calculated by linear regression
of the log-transformed concentrations of the last three
data points in the terminal phase. The half-life of the
elimination phase was calculated using the equation t1/2 =
0.693/ke. The body clearance (Cl) was calculated by
the relationship Cl = D/AUC0-∞, where D is the dose of
the drug. The mean residence time (MRT) was calcu-
lated from the ratio of AUMC/AUC, where AUMC is
the area under the first moment curve. The apparent
volume of distribution at steady state (Vss) was calculat-
ed from the relationship Vss = Cl × MRT. The peak
plasma concentration (Cmax) and the corresponding
time (Tmax) were directly obtained from the raw data.
Statistical analysis
Pharmacokinetic parameters of three emulsions via in-
travenous injection were compared by one-way analysis
of variance model. P < 0.05 was considered to be statis-
tically significant. All the data are expressed as mean ±
standard deviation ( xˉ ± s). Statistical analysis was per-
formed using DAS software (Q-DAS Inc. DAS 2.1.1).
RESULTS
Figures 1 and 2 show the mean plasma concentra-
tion-time profiles of tanshinone ⅡA and lithospermic
acid B after intravenous injection of EMU-AB,
EMU-A and EMU-B, respectively. Table 1 summarizes
relevant pharmacokinetic parameters.
The simultaneous administration of tanshinone Ⅱ A
and lithospermic acid B significantly altered each of
the pharmacokinetic parameters as compared with that
of tanshinone ⅡA or lithospermic acid B used sepa-
rately. The pharmacokinetic parameters of tanshinoneⅡA and lithospermic acid B in EMU-AB were signifi-
cantly altered as compared with that of tanshinone Ⅱ
A in EMU-A and lithospermic acid B in EMU-B. Re-
garding the EMU-AB group, in contrast with EMU-A
and EMU-B, the AUC0-∞ of tanshinoneⅡA and litho-
Figure 1 Profiles of the mean plasma concentration of tanshinone ⅡA versus time after intravenous injection of EMU-AB and
EMU-A in rats
EMU-AB: submicron emulsion of Danshen (Radix Salviae Miltiorrhizae), containing both tanshinoneⅡA and lithospermic acid B;
EMU-A: submicron emulsion of tanshinoneⅡA, containing tanshinoneⅡA.
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spermic acid B in rats increased by 18.35 and 59.31%,
respectively. The MRT of tanshinone ⅡA and litho-
spermic acid B lengthened, respectively, from 9.3 to
32.8 h and 20.2 to 49.1 h. The concomitant use of tan-
shinone ⅡA aggrandized the Vss and t1/2 of lithosper-
mic acid B, at the same time there was a significant
change in Vss and t1/2 of tanshinoneⅡA in the presence
of lithospermic acid B. Both the Vss and t1/2 of lithosper-
mic acid B and tanshinoneⅡA increased significantly.
DISCUSSION
It has been reported that tanshinone ⅡA may regulate
cytochrome P-450s (CYPs), which are associated with
metabolism and the body's elimination of drugs and
food.15 CYP1A1/1A2 participates in the metabolism of
not only drugs and food, but also in the metabolism of
arachidonic acid (AA). CYP2B1 is the main metabolic
enzyme for AA epoxidation. The epoxidation produc-
tion of AA may dilate blood vessels, mediate intra-cellu-
lar signaling pathway channels and elevate reactiveness
of the glutamic acid receptor in horizontal cell (HC).16
CYP2E1 generally participates in the metabolism of
various compounds. Tanshinone ⅡA may also influ-
ence the activity of glutathione transferase.17
The results from the present study showed that the
pharmacokinetic parameters of lithospermic acid B sig-
nificantly changed when used in combination with tan-
shinone Ⅱ A. These observations are consistent with
the results from a previous report that showed that tan-
shinone ⅡA may regulate CYPs. However, the contri-
bution of lithospermic acid B to the metabolic path-
way of tanshinone ⅡA remains unknown. Further re-
search should clarify the effects of lithospermic acid B
on the metabolic mechanism, especially the influence
of this compound on the metabolism of tanshinone Ⅱ
A. Both extracts are likely to not be homogenous com-
positions, but active fractions that include homologues
and these homologues may promote the synergistic ac-
tion of lithospermic acid B and tanshinoneⅡA.
In summary, EMU-AB, a combined use of tanshinoneⅡA and lithospermic acid B, may exert potential drug
interactions. In the present study, both the AUC0-t of
tanshinone ⅡA and that of lithospermic acid B were
significantly prolonged, indicating that the pharmaco-
dynamic action of both compounds may be enhanced.
In the clinic, both lithospermic acid B and tanshinoneⅡ A have preferably good therapeutic effects against
cardiovascular and liver diseases. With the rapid devel-
opment of drug delivery systems, it should be possible
to administer hydrophilic lithospermic acid B and lipo-
Parameter
AUC0-∞ (mg·h﹣1·L﹣1)
MRT (h)
Cl (L·h﹣1·kg﹣1)
Vss (L/kg)
t1/2 (h)
Tanshinone IIA (11 mg/kg)
EMU-AB
323.3612±14.3743
32.8377±0.6139
0.0341±0.0010
2.3503±0.5011
47.6121±9.5294
EMU-A
272.9242±14.8886
9.3288±0.5895
0.004±0.0000
0.0941±0.0204
16.2017±3.7388
Lithospermic acid B (23 mg/kg)
EMU-AB
980.7692±82.4375
49.0605±0.5942
0.0241±0.0020
2.5210±0.5208
75.4602±20.1265
EMU-B
615.7834±32.7085
20.2374±0.9202
0.0041±0.0000
0.0981±0.0070
18.2887±1.4702
Table 1 Pharmacokinetic parameters of tanshinoneⅡA and lithospermic acid B after i.v. injection of EMU-AB, EMU-A and EMU-B
in rats (n = 5, xˉ ± s)
Notes: EMU-AB: submicron emulsion of Danshen (Radix Salviae Miltiorrhizae), containing both tanshinone ⅡA and lithospermic acid
B; EMU-A: submicron emulsion of tanshinone ⅡA, containing tanshinone ⅡA; EMU-B: submicron emulsion of lithospermic acid B,
containing lithospermic acid B. TanshinoneⅡA in EMU-AB was significantly different (all P < 0.05) from that in EMU-A; Lithospermic
acid B in EMU-AB was significantly different (all P < 0.05) from that in EMU-B.
Figure 2 Profiles of the mean plasma concentration of lithospermic acid B versus time after intravenous injection of EMU-AB and
EMU-B in rats
EMU-AB: submicron emulsion of Danshen (Radix Salviae Miltiorrhizae), containing both tanshinoneⅡA and lithospermic acid B;
EMU-B: submicron emulsion of lithospermic acid B, containing lithospermic acid B.
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philic tanshinone ⅡA simultaneously. This study has
demonstrated that lithospermic acid B and tanshinoneⅡA may interact with each other following simultane-
ous intravenous injection in rats. However, the medical
significance needs to be proven by clinical trials.
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